EHA25 VIRTUAL MEETING

Next-generation BTK Inhibitors: A challenge for ibrutinib in B-cell Malignancies? Are the next-generation Bruton’s tyrosine kinase (BTK) inhibitors acalabrutinib and zanubrutinib poised to challenge ibrutinib’s position in the management of CLL and other forms of B-cell malignancy? We didn’t get the final answer to that question at EHA25 Virtual, but there was plenty of new […]

Read More…

--> EHA25 VIRTUAL MEETING

Subcutaneous Daratumumab Improves Clinical Outcomes in the Treatment of Patients with Amyloidosis The results of the ANDROMEDA phase 3 study of SC DARA + CyBorD in patients with newly diagnosed AL amyloidosis, which were presented during the Late-Breaking abstract session at EHA25, suggest that the combination has the potential to become the new standard of […]

Read More…

--> EHA25 Virtual

Today’s late-breaking abstract session at #EHA25Virtual saw Efstathios Kastritis present exciting new data for #daratumumab in systemic light chain (AL) amyloidosis, a rare condition that can cause serious damage to multiple organs and for which there are currently no approved therapies. – In the Phase 3 ANDROMEDA trial, the addition of daratumumab subcutaneous (SC) to cyclophosphamide-bortezomib-dexamethasone (CyBorD) resulted in […]

Read More…

--> Covid-19

Dear Friends and Colleagues These are uncertain and unprecedented times, as nCoV-19 affects the health and safety of people around the world, with Europe now the epicentre of the pandemic. Our top priority during this time is to protect the well-being of our employees, clients, partners and friends and importantly to ensure our continued ability […]

Read More…

-->